Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22555142 | 1.00 | PDK1 (0.47) | PDK1PDK2PDK3PDK4OPRM1 | |
| SCHEMBL22555109 | 0.85 | OPRM1 (0.44) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL22208222 | 0.85 | OPRM1 (0.44) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL30064999 | 0.85 | OPRM1 (0.44) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL3580101 | 0.85 | OPRM1 (0.44) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL651151 | 0.79 | STS (0.47) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL929751 | 0.79 | STS (0.47) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL30071078 | 0.79 | STS (0.47) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL29889592 | 0.73 | ABL1 (0.46) | OPRK1 | |
| SCHEMBL15818081 | 0.72 | TEAD1 (0.41) | PDK1PDK2PDK3PDK4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | PDK1 981/4885PDK2 2683/4885PDK3 3099/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PDK1 981/4885PDK2 2683/4885PDK3 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.